CoChat

Structural basis for differential inhibition of eukaryotic ribosomes by tigecycline

Open access
Li, Xiang, Wang, Mengjiao, Denk, Timo, Buschauer, Robert, Li, Yi, Beckmann, Roland, Cheng, Jingdong · 2024 · Nature Communications

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Tigecycline is widely used for treating complicated bacterial infections for which there are no effective drugs. It inhibits bacterial protein translation by blocking the ribosomal A-site. However, even though it is also cytotoxic for human cells, the molecular mechanism of its inhibition remains unclear. Here, we present cryo-EM structures of tigecycline-bound human mitochondrial 55S, 39S, cytoplasmic 80S and yeast cytoplasmic 80S ribosomes. We find that at clinically relevant concentrations, tigecycline effectively targets human 55S mitoribosomes, potentially, by hindering A-site tRNA accommodation and by blocking the peptidyl transfer center. In contrast, tigecycline does not bind to human 80S ribosomes under physiological concentrations. However, at high tigecycline concentrations, in addition to blocking the A-site, both human and yeast 80S ribosomes bind tigecycline at another conserved binding site restricting the movement of the L1 stalk. In conclusion, the observed distinct binding properties of tigecycline may guide new pathways for drug design and therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-49797-7

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Inhibitory properties of tigecycline on human ribosomes. a–c De novo mitochondrial (a, c) and cytoplasmic (b, c) nascent protein synthesis were measured by L-AHA labeling, followed by visualization of Alexa Fluor 488 fluorescence signal conjugated to L-AHA by “click reaction”. The intensity of the corresponding lines in the SDS-PAGE was analyzed using the ImageJ software. To estimate the IC50 value of tigecycline on the 55S mitoribosome in the mitochondrial lysate (Mito) and 80S human ribosome in the cytosolic lysate (Cyto), the intensities of positive controls derived from chloramphenicol (Cam) and CHX-treated samples, respectively, were subtracted. Second, the resulting intensities were normalized to the intensities of the negative controls, which in both cases were from the samples not treated with tigecycline. Note that tigecycline cannot sufficiently inhibit cytoplasmic translation even at high concentrations. Error bars (standard deviation) were calculated from at least three groups of protein bands whose intensities were quantified using ImageJ software (for mito, n = 4 groups; for cyto, n = 3 groups), and data were presented as mean values +/− SD. d In vitro translation of Nluc mRNA in HEK293T whole cell lysate in the presence of increasing concentrations of tigecycline. Error bars (standard deviation) were calculated from three different experimental units (n = 3 independent experiments), and data were presented as mean values +/− SD. e Cell viability of HEK293T cells in the presence of increasing concentrations of tigecycline, as measured by CCK-8 assay. Error bars (standard deviation) were calculated from three different experimental units (n = 3 independent experiments), and data were presented as mean values +/− SD. Source data are provided as a Source Data file.
Fig. 1 Inhibitory properties of tigecycline on human ribosomes. a–c De novo mitochondrial (a, c) and cytoplasmic (b, c) nascent protein synthesis were measured by L-AHA labeling, followed by visualization of Alexa Fluor 488 fluorescence signal conjugated to L-AHA by “click reaction”. The intensity of the corresponding lines in the SDS-PAGE was analyzed using the ImageJ software. To estimate the IC50 value of tigecycline on the 55S mitoribosome in the mitochondrial lysate (Mito) and 80S human ribosome in the cytosolic lysate (Cyto), the intensities of positive controls derived from chloramphenicol (Cam) and CHX-treated samples, respectively, were subtracted. Second, the resulting intensities were normalized to the intensities of the negative controls, which in both cases were from the samples not treated with tigecycline. Note that tigecycline cannot sufficiently inhibit cytoplasmic translation even at high concentrations. Error bars (standard deviation) were calculated from at least three groups of protein bands whose intensities were quantified using ImageJ software (for mito, n = 4 groups; for cyto, n = 3 groups), and data were presented as mean values +/− SD. d In vitro translation of Nluc mRNA in HEK293T whole cell lysate in the presence of increasing concentrations of tigecycline. Error bars (standard deviation) were calculated from three different experimental units (n = 3 independent experiments), and data were presented as mean values +/− SD. e Cell viability of HEK293T cells in the presence of increasing concentrations of tigecycline, as measured by CCK-8 assay. Error bars (standard deviation) were calculated from three different experimental units (n = 3 independent experiments), and data were presented as mean values +/− SD. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Cryo-EM structures of tigecycline on the human mitoribosome. a, b Overview (a) and cross-section (b) of the cryo-EM maps of the 55S mitoribosome (28S, yellow; 39S, gray) showing the binding sites of four tigecycline molecules (at various concentration levels, tomato red) within both the large and small subunits. The overview (a) of the 55S mitoribosome densities are shown in translucent, while the densities of the tigecycline molecules are not. c The details of tigecycline densities are shown. The Tig1-3 binding sites were consistent across all concentrations, except for Tig4, which only appeared under the 100 µM tigecycline condition. Densities for Tig2-4 are derived from the cryo-EM density map post-processed by DeepEMhancer, whereas the density of Tig1 were derived from the consensus map without post-processing.
Fig. 2 Cryo-EM structures of tigecycline on the human mitoribosome. a, b Overview (a) and cross-section (b) of the cryo-EM maps of the 55S mitoribosome (28S, yellow; 39S, gray) showing the binding sites of four tigecycline molecules (at various concentration levels, tomato red) within both the large and small subunits. The overview (a) of the 55S mitoribosome densities are shown in translucent, while the densities of the tigecycline molecules are not. c The details of tigecycline densities are shown. The Tig1-3 binding sites were consistent across all concentrations, except for Tig4, which only appeared under the 100 µM tigecycline condition. Densities for Tig2-4 are derived from the cryo-EM density map post-processed by DeepEMhancer, whereas the density of Tig1 were derived from the consensus map without post-processing.CC BY · PubMed Central
Fig. 3 Tigecycline blocks PTC on the human mitoribosome. a, b Overview of the 39S large subunit models of 55S (a) and 39S (b) mitoribosomes (16S rRNA, blue; 39S mitoribosomal proteins, gray) showing the Tig1 and Tig2 molecules (tomato red) within the peptidyl transfer center (PTC). The model originates from the human mitoribosome treated with 100 µM tigecycline. c The Tig1 molecule interacts in the PTC with the presence of a putative Mg ion (green). d Comparison with TcmX interaction in the PTC of the E. coli 70S ribosome. e The 55S mitoribosome with tigecycline structure compared to the translating one with A- and P-site tRNA and nascent peptide chain, indicating the potential clash of the Tig1 molecule with the nascent peptide in the peptide exit tunnel (PDB 6ZM5). f The detailed structure of the Tig2 molecule binding to H70 region of the 16S rRNA in the 55S mitoribosome with tigecycline. g The corresponding H70 region of the 16S rRNA in the 39S mitoribosome with tigecycline, indicating the absence of the Tig2 molecule. h The Tig2 molecule could affect the translocation of the tRNA from the A-site to the P-site. The conformation of base A1419 (A2602 in E. coli) would clash with the accommodated P-site tRNA. All key nucleotide bases are labeled. In some cases, the corresponding nucleotide bases in the E. coli 70S ribosome are also shown in gray.
Fig. 3 Tigecycline blocks PTC on the human mitoribosome. a, b Overview of the 39S large subunit models of 55S (a) and 39S (b) mitoribosomes (16S rRNA, blue; 39S mitoribosomal proteins, gray) showing the Tig1 and Tig2 molecules (tomato red) within the peptidyl transfer center (PTC). The model originates from the human mitoribosome treated with 100 µM tigecycline. c The Tig1 molecule interacts in the PTC with the presence of a putative Mg ion (green). d Comparison with TcmX interaction in the PTC of the E. coli 70S ribosome. e The 55S mitoribosome with tigecycline structure compared to the translating one with A- and P-site tRNA and nascent peptide chain, indicating the potential clash of the Tig1 molecule with the nascent peptide in the peptide exit tunnel (PDB 6ZM5). f The detailed structure of the Tig2 molecule binding to H70 region of the 16S rRNA in the 55S mitoribosome with tigecycline. g The corresponding H70 region of the 16S rRNA in the 39S mitoribosome with tigecycline, indicating the absence of the Tig2 molecule. h The Tig2 molecule could affect the translocation of the tRNA from the A-site to the P-site. The conformation of base A1419 (A2602 in E. coli) would clash with the accommodated P-site tRNA. All key nucleotide bases are labeled. In some cases, the corresponding nucleotide bases in the E. coli 70S ribosome are also shown in gray.CC BY · PubMed Central
Fig. 4 Tigecycline blocks the accommodation of A-site tRNA on the human mitoribosome. a Overview of the 28S small subunit model (rRNA, blue; mitoribosomal proteins, gray) showing the Tig3 and Tig4 molecules within the A-site and mRNA-binding channel of the 28S small subunit. b The Tig3 molecule interacts with h31 and h34 of the 12S rRNA near the A-site tRNA binding site. c Overlay the structures of the 28S small subunit with tigecycline and the bacterial 70S ribosome with tigecycline (PDB:4V9B) shows that the Tig3 molecule binds to the same “primary site” as the one (cyan) in the bacterial 70S ribosome. d The Tig4 molecule interacts with the h1 and h44 regions of the 12S rRNA within the mRNA-binding channel. e Superimposition of the 28S small subunit with tigecycline structure with the translation one (PDB 6ZM5) shows that the Tig3 and Tig4 molecules block the recognition of the A-tRNA anticodon and the mRNA codon, respectively.
Fig. 4 Tigecycline blocks the accommodation of A-site tRNA on the human mitoribosome. a Overview of the 28S small subunit model (rRNA, blue; mitoribosomal proteins, gray) showing the Tig3 and Tig4 molecules within the A-site and mRNA-binding channel of the 28S small subunit. b The Tig3 molecule interacts with h31 and h34 of the 12S rRNA near the A-site tRNA binding site. c Overlay the structures of the 28S small subunit with tigecycline and the bacterial 70S ribosome with tigecycline (PDB:4V9B) shows that the Tig3 molecule binds to the same “primary site” as the one (cyan) in the bacterial 70S ribosome. d The Tig4 molecule interacts with the h1 and h44 regions of the 12S rRNA within the mRNA-binding channel. e Superimposition of the 28S small subunit with tigecycline structure with the translation one (PDB 6ZM5) shows that the Tig3 and Tig4 molecules block the recognition of the A-tRNA anticodon and the mRNA codon, respectively.CC BY · PubMed Central
Fig. 5 Cryo-EM structure of tigecycline on the human 80S ribosome. a, b Overview of the cryo-EM structures of the human 80S ribosome incubated with either 4 µM (a) or 100 µM (b) tigecycline. The density of the 80S ribosome is shown as translucent, while the density of the tigecycline molecules is not. Two different views of Tig1-3 molecules are also shown as middle inserts. c The “primary” binding site (h31 and h34 region of 18S rRNA, blue) in human 80S ribosome. The tig3 molecule stacks well with base C1331 of the 28S rRNA. d Detailed structures of the Tig1-2 (tomato red) molecules binding sites within human 80S ribosomes near the L1 stalk. e The Tig1 and Tig2 molecules within the human 80S ribosome may affect the movement of 18S rRNA helix 23, thereby influencing 40S body rotation.
Fig. 5 Cryo-EM structure of tigecycline on the human 80S ribosome. a, b Overview of the cryo-EM structures of the human 80S ribosome incubated with either 4 µM (a) or 100 µM (b) tigecycline. The density of the 80S ribosome is shown as translucent, while the density of the tigecycline molecules is not. Two different views of Tig1-3 molecules are also shown as middle inserts. c The “primary” binding site (h31 and h34 region of 18S rRNA, blue) in human 80S ribosome. The tig3 molecule stacks well with base C1331 of the 28S rRNA. d Detailed structures of the Tig1-2 (tomato red) molecules binding sites within human 80S ribosomes near the L1 stalk. e The Tig1 and Tig2 molecules within the human 80S ribosome may affect the movement of 18S rRNA helix 23, thereby influencing 40S body rotation.CC BY · PubMed Central
Fig. 6 Cryo-EM structure of tigecycline on the eukaryotic 80S ribosome. a The sliced view of the human and yeast 80S ribosome structures. Translation factors are highlighted in distinct colors. b Overview of cryo-EM maps of human and yeast 80S ribosomes (40S, yellow; 60S, gray) showing nine and six tigecycline (tomato red) molecules within the large and small subunits, respectively. The 80S ribosome densities are shown in translucent, while the densities of the tigecycline molecules are not. All densities are derived from the cryo-EM density map post-processed by DeepEMhancer.
Fig. 6 Cryo-EM structure of tigecycline on the eukaryotic 80S ribosome. a The sliced view of the human and yeast 80S ribosome structures. Translation factors are highlighted in distinct colors. b Overview of cryo-EM maps of human and yeast 80S ribosomes (40S, yellow; 60S, gray) showing nine and six tigecycline (tomato red) molecules within the large and small subunits, respectively. The 80S ribosome densities are shown in translucent, while the densities of the tigecycline molecules are not. All densities are derived from the cryo-EM density map post-processed by DeepEMhancer.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 21

Metadata

Authors
Li, X., Wang, M., Denk, T., Buschauer, R., Li, Y., Beckmann, R., & Cheng, J.
Affiliations
  • Shanghai Medical College of Fudan University (CN)
  • Ludwig-Maximilians-Universität München (DE)
Corresponding author
  • Beckmann, Roland
  • Cheng, Jingdong
Venue
Nature Communications
Published
2024-06-28
Volume
15
Issue
1
Pages
5481-5481
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4400119210
Cited by
21
References
53
Citations by year
2026: 11 · 2025: 10
FWCI
2.86
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Ministry of Science and Technology of the People’s Republic of China (2023YFC2413204)
  • National Natural Science Foundation of China (32371350)
  • Science and Technology Commission of Shanghai Municipality (22ZR1413600, 22410712400)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
Keywords
tigecycline, ribosome inhibition, 80S ribosome, mitochondrial ribosome, cryo-EM structure, drug binding sites, antibiotic mechanism of action
MeSH terms
Mitochondrial Ribosomes, Tigecycline, Anti-Bacterial Agents, Binding Sites, Humans, Models, Molecular, Ribosomes, RNA, Transfer, Saccharomyces cerevisiae, Protein Biosynthesis, Cryoelectron Microscopy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural basis for differential inhibition of eukaryotic ribosomes by tigecycline. https://app.cochat.ai/papers/10.1038/s41467-024-49797-7
The paper
Li, X., Wang, M., Denk, T., Buschauer, R., Li, Y., Beckmann, R., & Cheng, J. (2024). Structural basis for differential inhibition of eukaryotic ribosomes by tigecycline. Nature Communications. https://doi.org/10.1038/s41467-024-49797-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.